NCT05031962View on ClinicalTrials.gov

Safety and Clinical Performance of a Biological Matrix Used in Implant-based Breast Reconstruction

Active, not recruitingOBSERVATIONAL
Enrollment

112

Participants

Timeline

Start Date

October 4, 2021

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Breast Reconstruction Following Mastectomy
Interventions
DEVICE

CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)

Biological membrane used in breast reconstruction

Trial Locations (10)

31059

IUCT Oncopole, Toulouse

33076

Institut Bergonié, Bordeaux

59000

Centre Oscar Lambret, Lille

68024

Hôpitaux civils de Colmar, Colmar

69373

Centre Léon Bérard, Lyon

75015

Hôpital Européen Georges Pompidou, Paris

75020

Hôpital Tenon, Paris

92100

Hôpital Ambroise Paré, Boulogne-Billancourt

94800

lnstitut Gustave Roussy, Villejuif

44 805

Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain

Sponsors

Lead Sponsor

Meccellis Biotech
All Listed Sponsors
lead

Meccellis Biotech

INDUSTRY

NCT05031962 - Safety and Clinical Performance of a Biological Matrix Used in Implant-based Breast Reconstruction | Biotech Hunter | Biotech Hunter